Symposia with Industry Support
Tuesday, May 1: 7:00-9:00 a.m.
Novel Developments in Glutamate Modulation for Schizophrenia: How Can Psychiatric Pharmacists Impact Care in the Paradigm Shift from Dopamine to Glutamate?
In the May 2011 closing keynote session of the College of Psychiatric and Neurological Pharmacists (CPNP), Dr Stephen Stahl discussed glutamatergic neurotransmitter systems and relevant compounds, including glycine transport inhibitors and metabotropic glutamate receptor 2,3-selective agonists.
The intent of this symposium will be to provide next-steps in the transfer of knowledge about glycine-type 1 inhibitors with a goal to achieve competence pertaining to new options in schizophrenia medication management. A combination of presentations, case-studies, and discussion will provide attendees with an interactive and engaging educational experience.
Faculty
Vicki L. Ellingrod, PharmD, BCPP, FCCP
Head, Clinical Pharmacogenomics Laboratory
Associate Professor, College of Pharmacy and
Associate Professor, College of Medicine
Department of Psychiatry
University of Michigan
Ann Arbor, MI
Larry Ereshefsky, PharmD, FCCP, BCPP
Vice President, Principal Consultant and Global Therapeutic Leader, Psychiatry
Chief Scientific Officer
California Clinical Trials Medical Group
Marina del Rey, CA
Adjunct Professor of Pharmacology
University of Texas Health Science Center,
San Antonio, TX
Registration:
Participants must register using the online form. Additional information can be found at www.primeinc.org/CPNP.
Additional Information
Learning Objectives
- Evaluate the functionality and dysregulation of the glutamatergic neurochemical pathway pertaining to the pathophysiology of schizophrenia
- Differentiate mechanisms of action and potential value of glutamate system modulators in the treatment of schizophrenia
- Compare and contrast medication management strategies to improve outcomes
Agenda
I. Current State of the Science in schizophrenia medication management
- Where we left off at the closing keynote session, 2011
- Evidence in modulating gultamatergic neurotransmitter system and relevant compounds
II. Emerging Gly-T1 inhibitors, mGluR2/3 agonists and glycine/D-serine site agonists
- Differentiating mechanisms of action
- Evaluating efficacy and safety for treatment of negative symptoms
III. Questions and Answers
IV. Case-studies in schizophrenia medication management
Continuing Education Credit
This curriculum has been approved for 1.5 contact hours by PRIME®. PRIME® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is 0255-0000-12-011-L01-P. This learning activity is Application-based.
Offered by:
Supported by:
